This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

QT Variability Pre and Post Cardioversion (DCCV)

This study has been completed.
National Institutes of Health (NIH)
Wake Forest University Health Sciences
Information provided by (Responsible Party):
Dawood Darbar, Vanderbilt University Identifier:
First received: April 20, 2009
Last updated: December 9, 2014
Last verified: December 2014
The purpose of this study is to learn whether the chemicals in the blood and urine are different when the heart is atrial fibrillation compared to normal sinus rhythm.

Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: QT Variability Pre & Post Cardioversion in Patient's With Atrial Fibrillation

Resource links provided by NLM:

Further study details as provided by Dawood Darbar, Vanderbilt University:

Primary Outcome Measures:
  • QT variability before and after direct current cardioversion [ Time Frame: 1.5 ]

Biospecimen Retention:   Samples With DNA
Blood sample

Enrollment: 219
Study Start Date: January 2007
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Detailed Description:
Atrial Fibrillation variably activates the renin-angiotensin-aldosterone system (RAAS), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increases ventricular rate. These are interrelated responses and the extent to which these or other pathophysiologic responses determine QT interval during and after Atrial Fibrillation (AF) is unknown. In this study, the QT variability is related to those potential markers in patients with AF undergoing elective DC-cardioversion.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Cardiology Clinic Hospital inpatient

Inclusion Criteria:

  • At least 21 years of age
  • Scheduled to undergo an elective DC-Cardioversion of atrial fibrillation or atrial flutter at Vanderbilt University Medical Center

Exclusion Criteria:

  • Undergoing emergent DC-Cardioversion of atrial fibrillation for hemodynamic instability
  • Undergoing DC-Cardioversion for post-cardiac surgery
  • Dual chamber pacemakers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00885391

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-0575
Sponsors and Collaborators
Vanderbilt University
National Institutes of Health (NIH)
Wake Forest University Health Sciences
Principal Investigator: Dawood Darbar, M.D., Ph.D., F.A.C.C. Vanderbilt University Medical Center
  More Information

Responsible Party: Dawood Darbar, Associate Professor of Medicine and Pharmacology, Vanderbilt University Identifier: NCT00885391     History of Changes
Other Study ID Numbers: 060908
R01HL085690-01A2 ( U.S. NIH Grant/Contract )
Study First Received: April 20, 2009
Last Updated: December 9, 2014

Keywords provided by Dawood Darbar, Vanderbilt University:
Atrial Fibrillation
Direct Current Cardioversion
QT Interval

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes processed this record on September 21, 2017